30 results about "Fibrotic lesion" patented technology

Methods and compositions for the treatment of fibrosing diseases are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of CCL21 either alone or in combination with CCL19 will be effective in reducing the presence of fibrotic lesions and ameliorating the symptoms of fibrosing disorders.

The invention relates to a microneedle patch for treating keloid as well as a kit and application. The microneedle patch does not contain medicine, and comprises a substrate and a microneedle array arranged on the substrate, wherein the microneedle array comprises a plurality of microneedles; the gap between each microneedle is not smaller than 200 microns; each microneedle length is 300 to 1000 microns; the microneedle material is nonmetal which cannot generate swelling on the skin, cannot be softened and cannot cause skin itch or irritability. The microneedle patch does not depend on medicine or other bioactive substances for inhibiting the growth of fibrotic lesion; the treatment mode has the cost advantage and has a small side effect.

The invention relates to protecting functions and applications of FSTL1 in anti-fibrosis steady-state regulation of tissues such as livers, and particularly relates to uses of FSTL1 protein or an FSTL1 regulating compound in preparation of medicines treating tissue fibrosis diseases. The invention also relates to a conditional FSTL1 gene knockout non-human animal model closely related to the degree of tissue fibrosis pathological changes, a preparing method thereof and uses of the model in tissue-fibrosis-preventing medicine screening. Treatment is performed by combining different tamoxifen dosages and different animal growth stages, the systemic or vascular endothelial cell FSTL1 gene knockout non-human animal model is obtained and the model is used for simulating different tissue fibrosis pathological changes.

The invention relates to the new applications of integrin beta 4 binding protein (ITGB4BP) and derivates thereof, or gene recombinant expression vector expressing the ITGB4BP or derivates thereof in preventing and/or treating hypertrophic scar or fibrosis lesion; wherein, the amino acid sequence of the ITGB4GB is SEQ ID NO 1; the derivates of the ITGB4BP are protein derivates retaining the combining site and the functional site of the ITGB4BP (SEQ ID NO 1). The application is realized by applying the ITGB4BP or derivates thereof, or gene recombinant expression vector expressing the ITGB4BP orderivates thereof, or the drug combination or the kit of the invention on subjects with an effective dose in treatment. The drug combination or the kit contains the ITGB4BP or derivates thereof, or gene recombinant expression vector expressing the ITGB4BP or derivates thereof and an officinal excipient or vectors and the like with an effective dose in treatment. Preferably, the subjects are humanbeings or animals.

The invention discloses a lung caring pill, belonging to traditional Chinese medicine preparations. The lung caring pill comprises the following active pharmaceutical ingredients in certain parts by weight: bulbus fritilariae, almond, pseudo-ginseng, lumbricus amd ephedra. The lung caring pill is used for treating bronchitis and chronic bronchitis, and the effective rate for preventing pulmonary fibrosis is up to 91.2%; and the toxicity test and clinical practice prove that the medicine is safe and effective and has no toxic or side effect. The medicine can have the effects of moistening the lung, resolving the phlegm, promoting the dispersing function of the lung, regulating the flow of qi and relieving cough and asthma. The lung caring pill does not have a therapeutic action on the formed fibrosis pathological changes, but can reinforce the blood flow of the partial capillary network, improve the pulmonary alveolus function, promote the extinction of the bronchus chronic inflammation, decrease the inflammatory exudation and prevent pulmonary fibrosis from further development. The lung caring pill has the characteristics of definite curative effect, high safety and high economical performance.

Provided is a traditional Chinese medicine combination for treating chronic hepatitis with hepatic fibrosis and liver cirrhosis. The medicine combination consists of 12 traditional Chinese medicine constituents, radix astragali, radix condonopsis, angelica sinensis, radix paeoniae alba, radix curcumae, salvia miltiorrhiza, turtle shell, tortoiseshell, caulis spatholobi, rhizome sparganii, curcuma zedoary, peach kernel and more. The medicine combination can be prepared into various oral preparations such as health care product, food product, admixture, pills, tablets, capsules, granules and more. The traditional Chinese medicine combination is clinically proved to have outstanding treatment effects on patients with a variety of hepatoses, especially on patients with chronic hepatitis accompanied by fibrotic lesions or liver cirrhosis not accompanied by hemorrhagic tendencies. The traditional Chinese medicine combination employs traditional Chinese medicine treatment theory; patients are diagnosed and treated by arguments of blood stasis due to stagnation of qi, hepatic stagnation causing splenic deficiency, hypofunctioning of spleen and stomach, hepatic and renal yin deficiency, toxin generated by accumulation of damp heat, and others. The traditional Chinese medicine combination starts with etiology and pathogenesis, and treats with soothing liver and strengthening spleen, promoting qi to activate blood, dissolving stasis and eliminating symptoms, nourishing liver and kidney, cooling blood and eliminating stasis. The traditional Chinese medicine combination has a good clinical curative effect on symptoms like hepatitis fibrosis and liver cirrhosis.

The invention discloses the application of a Lefty protein in prohibiting fibering pathologic change of organs, in basic research on preparing the medicine for antagonizing TGF-beta, Nodal, BMP, p³⁸MAPK signal pathways, and in preparing the medicine for curing or preventing fibering pathologic change of organs and tissues of liver, kidney, lung, cardiac muscle, skin, etc. The invention has the functions of prohibiting signal pathways (such as TGF-beta/Smad, Nodal signal pathways) related to fibering diseases and activating protein hydrolytic ferment (such as MMP, gelatingase, etc) capable of prohibiting fibering, is a biological preparation with great potential clinical application value, and can help to further probe into the occurring mechanism of fibering diseases.

New therapeutic use of Polypodium extract. A new use of Polypodacea genus extracts is described for the treatment of fibrotic pathologies, such as, scleroderma, pulmonary fibrosis, atherosclerosis, bone marrow fibrosis, liver fibrosis, pancreatic fibrosis, kidney fibrosis, cardiac fibrosis, Dupuytrem's disease and, specially, Peyronie's disease; said fibrotic pathologies are produced by an extracellular matriz (ECM) overexpresion, and by a Transforming Growth Factor (TFG-β) overexpression. It is disclosed extracellular matriz inhibition in vitro; and penis tunica albuginea reduction and plaque redution in patients who suffer Peyronie's diseaseas after Polypodium extracts administration. In a preferred mode, Polypodium extracts are obtained from Polypodium leucotomos rhizomes and extraction with a polar solvent.

The invention discloses a construction method of a metabolism-related fatty liver disease non-human primate model, and belongs to the technical field of experimental animals. According to the construction method, non-human primate animals, namely cynomolgus monkeys, are used as model animals, and are fed with high-fat, high-sugar and high-cholesterol feed, so that the glycolipid metabolism disorder phenomenon that the weight of the animals is increased along with the feeding time, and the blood glucose, cholesterol and triglyceride levels are remarkably increased is avoided; therefore, liver fat accumulation and fibrosis lesion are caused. The metabolism-related fatty liver disease non-human primate animal model constructed by the invention can simulate the occurrence and development of the metabolism-related fatty liver in physiological and pathological processes caused by improper diet of human beings, and a preclinical evaluation tool is provided for developing the research and development of nutrients and medicines in related fields.

The invention discloses application of an MMI-0100 oligopeptide compound in preparation of a medicine for treating cholestatic liver diseases. The amino acid sequence of the MMI-0100 oligopeptide compound is as follows: YARAAARQARAKALARQLGVAA. After MMI-0100 drug treatment, the fibrosis lesion of the mouse liver is relieved, the infiltration of inflammatory cells is reduced, meanwhile, the hyperplasia degree of the bile duct is relieved, the mRNA expression level of the liver fibrosis gene alpha-SMA is reduced, and the results show that the MMI-0100 has a good treatment effect on the cholestatic liver injury.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to the application of a chicken gall conversion product in preparing a medicine for preventing and/ or curing liver fibrosis. According to the application, a liver fibrosis rat model of di-methyl-nitrosamine is used for treating the chicken gall conversion product to reduce liver collagen deposition degree and improve liver inflammatory and fibrotic pathological changes, has the function of liver fibrosis lesion resistance, and can be used for preparing the anti-liver fibrosis medicine. The chicken gall conversion product serves as an active ingredient for restraining and/ or reversing liver fibrosis in the anti-liver fibrosis medicine, the mass percent of the chicken gall conversion product is 10%-95%, the suppression and/ or reversion of the liver fibrosis can be achieved by improving hepatic cell inflammation and/ or improving hepatic cell repair and/ or restraining liver fibrosis lesion, and the medical application prospects are wide.

The present invention discloses one kind of conic gymnadenia tuber extract and its application in preparing medicine for treating pulmonary fibrosis. The conic gymnadenia tuber extract is prepared through crushing conic gymnadenia tuber, sieving to obtain conic gymnadenia tuber powder, soaking the conic gymnadenia tuber powder in 50-70 % concentration alcohol water solution of 4-10 time volume for 18-30 hr, heating reflux to extract for 0.5-3 hr, filtering, repeating the extraction step for 1-3 times, merging the filtrate, decompression concentrating to density at 50 deg.c of 1.05-1.2. Experiment proves the treating effect of the conic gymnadenia tuber extract on pulmonary silicosis, and this reveals its use value in treating other pulmonary fibrosis diseases.

The invention relates to technical field of medical treatment and discloses a medicine for preventing hepatic fibrosis and a preparation method of the medicine. The medicine is prepared from the following components: 13 to 20 parts of radix angelicae sinensis extract, 8 to 13 parts of safflower extract, 5 to 10 parts of rhizoma zingiberis, 9 to 18 parts of semen gleditsiae sinensis extract and 7 to 14 parts of rhizoma chuanxiong extract. The medicine for preventing the hepatic fibrosis, disclosed by the invention, has the abilities of reducing liver damage and subsequent fibrosis lesions caused by alcohol; a key cell, namely the hepatic stellate cell, formed by fibrosis tissues can be directly inhibited; in addition, by protecting the liver, liver damage, steatosis and inflammation causedby the alcohol are inhibited, thereby delaying the pathogenetic process of liver fibrosis.